The Superior Court of Quebec has issued a permanent injunction preventing Montreal-based online retailer Canlab Research from selling injectable peptides in Canada, after Health Canada said the company had been marketing and distributing products without regulatory approval.
Federal regulator says sales posed health risks
In a news release, Health Canada said Canlab Research advertised and sold peptides on multiple websites while asserting unproven health benefits. The agency treats many peptides as prescription drugs, and it has increasingly moved against businesses across Canada that promote injectable peptides for uses such as bodybuilding, injury recovery, anti‑aging or improved mental focus.
Health Canada warned that unauthorized peptide use can produce serious adverse effects, including hormonal imbalances, mood disturbances, liver or kidney damage, blood clots and the potential promotion of cancerous tumour growth. The regulator noted the importance of obtaining prescription medication through licensed pharmacies and in consultation with a health‑care professional.
"think twice"
The injunction follows an advisory Health Canada issued in April urging people to "think twice" before using injectable peptides purchased online and a previous order directing Canlab Research to stop advertising and selling the products.
Enforcement and consumer guidance
Health Canada has in recent years stepped up enforcement against companies it says exploit regulatory gaps to market peptides directly to consumers. While regulators classify many peptides as requiring prescription oversight, vendors have been able to reach buyers through online storefronts, social media and third‑party marketplaces.
- Regulatory status: Many peptides are treated as prescription drugs by Health Canada.
- Risks cited: Hormonal disruption, organ damage, blood clots, possible tumour growth.
- Consumer advice: Obtain prescription medicines from a licensed pharmacy and consult a health‑care professional.
What the injunction means
The court order is permanent, meaning Canlab Research is legally barred from continuing to sell the injectable peptides targeted in Health Canada’s proceedings. The injunction follows earlier administrative measures by the regulator to halt advertising and commerce of the disputed products.
The ruling reinforces the federal agency’s position that unapproved distribution of prescription‑class products is unlawful and potentially dangerous. It also signals that courts are willing to back the regulator’s efforts to protect Canadians from marketed therapies lacking approval and adequate safety data.
| Issue | Health Canada position |
|---|---|
| Sale of injectable peptides | Unauthorized; many are treated as prescription drugs |
| Consumer risks | Hormonal and organ harms; blood clots; potential tumour growth |
| Regulatory action | Advisories, stop‑sale orders, and now a permanent injunction |
Health Canada’s enforcement campaign has targeted a number of companies in different provinces. The regulator’s public communications have sought to counter claims made by vendors about peptides’ effectiveness and safety, stressing that any decisions about prescription medicines should involve licensed health‑care professionals.
For consumers, the ruling is a reminder of the dangers of buying injectable products outside regulated pharmacies and professional oversight. Health Canada’s action may discourage other sellers operating in similar online channels and could prompt platforms hosting such advertisements to increase scrutiny.
With the court’s permanent injunction now in place, Health Canada will continue monitoring compliance and taking action where it determines unauthorized medical products are being marketed or sold across Canada.
